Postoperative nausea and vomiting (PONV) is the common complication of nausea, vomiting, or retching experienced by a person within the first 24 hours following a surgical procedure. Untreated, PONV affects about 30% of people undergoing general anesthesia each year, with rates rising to 70–80% among those considered high-risk. Postoperative nausea and vomiting can be highly distressing for people undergoing surgery and may pose significant barriers towards recovery, cause surgical complications, and result in delayed discharge from the surgical center if not managed properly.
Cause
Risk factors Risk factors for PONV can be classified into three main categories: patient-related, surgical, and anesthetic-related.
Patient-related Patient factors that confer increased risk for PONV include female gender, younger age (<16 years old), obesity, non-smoking status, high levels of preoperative anxiety, and prior history of PONV, motion sickness, or chemotherapy-induced nausea. The Apfel risk-scoring system is commonly used to sensitively and specifically determine the risk of PONV in adults. This simplified scoring system considers four primary predictors:
Female sex (most reliable) Non-smoking status History of PONV or motion sickness Post-operative opioid use The presence of 0, 1, 2, 3, or 4 factors corresponds to PONV risks of approximately 10%, 20%, 40%, 70%, and 80%, respectively. Research has also shown a genetic disposition towards PONV. Certain procedure types such as gynecological, abdominal, laparoscopic, ENT surgeries, and strabismus surgery in children are associated with a modestly increased risk of PONV versus other general surgical procedures.
Anesthetic-related The type of anesthetic medication plays a role in the risk for nausea and vomiting after surgery. Several medications routinely used in anesthesiology are believed to contribute to nausea and vomiting by acting on the highly sensitive chemoreceptor trigger zone (CTZ) located in the area postrema in the medulla oblangata, although the exact mechanisms remain poorly understood. Prolonged exposure to these drugs, namely volatile anesthetics, nitrous oxide (N2O), physostigmine, and opioids has been found to be correlated with increased PONV risk. The approach taken to anesthesia may also play a role in the risk of nausea and vomiting post-operatively. A significant body of evidence indicates that total intravenous anesthesia (TIVA) using propofol for induction and maintenance can reduce the incidence of postoperative nausea and vomiting significantly in both adults and children (3.5-fold vs. 5.7-fold reduction respectively) in comparison to volatile-anesthetic based techniques. Regional anesthesia has also demonstrated better outcomes for patients when compared to its general counterpart.
Mechanism The pathophysiology of PONV is mediated by several key neurotransmitters, including histamine, dopamine, serotonin, acetylcholine, and the more recently recognized neurokinin-1 (substance P). Pharmacologic stimulation of different chemoreceptors in the brain trigger different pathways that can result in PONV. Additionally, direct surgical manipulation of the vestibular system (cranial nerve VIII) or gastrointestinal structures innervated by the vagus nerve (cranial nerve X) can further activate the neural pathways involved in precipitating nausea and vomiting.
Prevention Key strategies in the prevention of postoperative nausea and vomiting include diligent risk assessment and stratification, use of non-volatile anesthetic techniques when feasible, provision of preventative medications based on risk, and employment of multimodal, opioid-sparing techniques for surgical pain control. Optimizing intravascular fluid volume during surgery is another strategy to reduce the risk of PONV, often achieved by administering additional IV fluids under general anesthesia. This approach addresses the fluid deficit caused by preoperative fasting, which typically restricts oral fluid intake for 2–6 hours before surgery. There is some evidence that providing the person undergoing anesthesia with supplemental perioperative intravenous crystalloids may reduce vomiting and/or nausea in patients with certain characteristics (American Society of Anesthesiologists (ASA) class I and II patients). The potential risks and other adverse effects with this type of therapy are unknown. For minor surgical procedures, more research is needed to determine the risks and benefits of this approach.
Management Commonly administered medications like serotonin receptor antagonists (ondansetron), corticosteroids (dexamethasone), and neurokinin-1 receptor antagonists (aprepitant) primarily act by modifying the release and activity of the aforementioned neurotransmitters involved in nausea and vomiting, effectively reducing the incidence of PONV. Using a multimodal approach by combining drugs targeting different receptors involved in PONV has been shown to be more efficacious than monotherapy. However, numerous patient factors, adverse side effects, and cost-effectiveness of these medications must be taken into consideration when selecting a treatment regimen. Recent evidence has shown that alternative therapies may also play a role in decreasing the incidence of PONV when used in conjunction with conventional treatment.
… excerpt ends here. Continue reading the full article.
